Inventor

RÖDER HEINRICH

US25 patents

⚠️ This page may combine multiple inventors who share the name “RÖDER HEINRICH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

RÖDER HEINRICH

BIODESIX INC

Classification generation method using combination of mini-classifiers with regularization and uses thereof

Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof

Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents

Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample

Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample

Method of predicting development and severity of graft-versus-host disease

Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry

Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry

Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

Deep MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof

Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample

Method for predicting breast cancer patient response to combination therapy

Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies

Treatment selection for lung cancer patients using mass spectrum of blood-based sample

Bagged filtering method for selection and deselection of features for classification

Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings

Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings

Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups

Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies

Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy

Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy

RÖDER HEINRICH

Method and system for determining whether a drug will be effective on a patient with a disease

Method and system for determining whether a drug will be effective on a patient with a disease

RÖDER JOANNA

Method for predicting breast cancer patient response to endocrine therapy